The U.S. Food and Drug Administration approved Swiss drugmaker Idorsia’s treatment for insomnia in adult patients.

Eisai Inc. announced that JAMA Network Open published results of SUNRISE 1 (Study 304), a pivotal Phase 3 head-to-head study that compared Dayvigo (lemborexant) to placebo and an active comparator in patients with insomnia disorder.

The U.S. regulatory agency approved Eisai Inc.’s Dayvigo in doses of 5 mg and 10 mg based on two late-stage studies testing the drug in patients with insomnia versus placebo for up to one month and six months.

Pear Therapeutics announced the filing of a submission to the U.S. Food and Drug Administration seeking marketing authorization for Somryst, a prescription digital therapeutic (PDT) intended for use in the treatment of adults with chronic insomnia and depression.

In March, just one month after Merck introduced its new insomnia drug, Belsomra, physicians were writing 4,000 prescriptions a week for the new product—enough for CEO Kenneth Frazier to declare […]